PMID- 12030423
OWN - NLM
STAT- MEDLINE
DCOM- 20021202
LR  - 20160321
IS  - 0953-1424 (Print)
IS  - 0953-1424 (Linking)
VI  - 15
IP  - 1-2
DP  - 2002 Mar
TI  - High magnesium concentration in vitro decreases human leukocyte activation.
PG  - 43-8
AB  - In view of experimental data suggesting that pharmacological magnesium (Mg) 
      therapy could be expected to temper hypersensitivity, the aim of the present 
      study was to assess the effect of in vitro high Mg concentration (8 mmol/l vs. 
      0.8 mmol/l) on human leukocyte activation. The first experiment in nine healthy 
      volunteers was performed on total leukocyte suspension containing 82 +/- 4 per 
      cent of neutrophils. The results demonstrate the inhibitory effect of high Mg 
      concentration as shown by the significant reduction of superoxide anion 
      production following phorbol myristate acetate (PMA) or 
      formyl-methionyl-leucyl-phenylalanine (fMLP) activation. Moreover, neutrophils 
      activated with fMLP showed an increased respiratory burst when incubated in low 
      Mg concentration (0.2 mmol/l) as compared to normal Mg concentration (0.8 
      mmol/l). Similarly, high concentration of Mg resulted in a significant reduction 
      in superoxide anion production by eosinophils in response to PMA in five 
      eosinophilic patients. In patients showing Hymenoptera venom hypersensitivity, 
      high Mg concentration resulted in a significant reduction of sulphidoleukotrienes 
      production by leukocytes in response to venom allergen (six patients) or in 
      response to zymosan activated particules (fourteen patients). Taken together, the 
      results suggests that Mg acts via a non specific mechanism and appears to be non 
      specific to a particular cell type. As Mg counteracts calcium in many 
      physiological and pathological processes, it is reasonable to hypothesise that 
      extracellular Mg can diminish leukocyte activation by its calcium antagonism.
FAU - Bussiere, F I
AU  - Bussiere FI
AD  - Centre de Recherches en Nutrition Humaine, Unite Maladies Metaboliques et 
      Micronutriments, INRA-Theix, Saint-Genes-Champanelle, France.
FAU - Mazur, A
AU  - Mazur A
FAU - Fauquert, J L
AU  - Fauquert JL
FAU - Labbe, A
AU  - Labbe A
FAU - Rayssiguier, Y
AU  - Rayssiguier Y
FAU - Tridon, A
AU  - Tridon A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Magnes Res
JT  - Magnesium research
JID - 8900948
RN  - 0 (Anions)
RN  - 0 (Leukotrienes)
RN  - 0 (Reactive Oxygen Species)
RN  - 11062-77-4 (Superoxides)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - I38ZP9992A (Magnesium)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
RN  - S88TT14065 (Oxygen)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Anions
MH  - Calcium/antagonists & inhibitors
MH  - Eosinophils/metabolism
MH  - Humans
MH  - In Vitro Techniques
MH  - Leukocytes/*metabolism
MH  - Leukotrienes/metabolism
MH  - Magnesium/metabolism/*pharmacology
MH  - N-Formylmethionine Leucyl-Phenylalanine/pharmacology
MH  - *Neutrophil Activation
MH  - Oxygen/metabolism
MH  - Reactive Oxygen Species
MH  - Superoxides
MH  - Tetradecanoylphorbol Acetate/pharmacology
EDAT- 2002/05/28 10:00
MHDA- 2002/12/03 04:00
CRDT- 2002/05/28 10:00
PHST- 2002/05/28 10:00 [pubmed]
PHST- 2002/12/03 04:00 [medline]
PHST- 2002/05/28 10:00 [entrez]
PST - ppublish
SO  - Magnes Res. 2002 Mar;15(1-2):43-8.